| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Endocrinology, Karolinska Hospital (K.H., G.E.), and the Polypeptide Laboratory, AB Kabi (J.B., L.F.) Stockholm, Sweden
Address requests for reprints to: Kerstin Hall, M.D., Department of Endocrinology, Karolinska Hospital, S-104 01 Stockholm, Sweden.
A RIA has been developed for somatomedin A (SM-A) utilizing Sepharose-bound antibodies. This assay, measuring SM-A, the insulin-like growth factors 1 and 2, and somatomedin C, allows determination in serum samples. In comparison with a serum standard, the mean serum levels in patients with acromegaly or GH deficiency and healthy subjects were 8.7 ± 0.7 (n = 25), 0.24 ± 0.02 (n = 25), and 1.15 ± 0.11 U/ml, respectively. The correlation coefficient between immunoreactive SM-A and SM-A by radioreceptor assay was highly significant (r = 0.93), although the potency ratio of SM-A between the two groups of patients was higher in the RIA than in the radioreceptor assay. Gel chromatography revealed that SM-A in acromegalic serum is bound to a carrier protein which is absent in patients with GH deficiency. After gel chromatography at low pH, 90% of applied immunoreactive SM-A was recovered in the low molecular weight fraction and consisted mainly of neutral polypeptides. (J Clin Endocrinol Metab 48: 271, 1979)
* This work was supported by grants from Swedish Medical Research Council (19X-4224) and Svenska Läkarsällskapet.
Received February 27, 1978.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |